Business Wire

Knopp Biosciences Announces Renewal of NIH Blueprint Grant Award for Advancing KCNQ2 Modulators in Epilepsy

Del

Knopp Biosciences LLC today announced the renewal and expansion of its grant award from the National Institutes of Health Blueprint Neurotherapeutics Network to advance novel treatments for epilepsy.

The Phase 2 award under the NIH Small Business Innovation Research (SBIR) program anticipates NIH support of up to $2 million over the next three years of the project, subject to satisfactory completion of milestones. The renewal follows the successful completion of all milestones under a previously awarded Phase 1 grant of $400,000.

Knopp is directing its potassium channel activator program to preclinical and clinical development of small-molecule drug candidates against a validated, anti-seizure pharmaceutical target encoded by the KCNQ2 gene. Knopp intends to advance novel, small-molecule KCNQ2 activators in neonatal epileptic encephalopathy, a rare disorder caused by inherited mutations in the KCNQ2 gene. Neonatal epileptic encephalopathy is characterized by persistent seizures from the beginning of life and profound developmental disability in children for whom conventional anti-seizure medications are insufficient or ineffective.

Knopp President and CEO Michael Bozik, M.D., a neurologist with clinical development expertise in potassium channel modulators, serves as Principal Investigator on the Blueprint grant. "This Phase 2 award recognizes the need to go beyond seizure control to treat the underlying causes of epilepsy,” he said. “We are very pleased with the renewal of the NIH Blueprint grant and its emphasis on innovative approaches in the treatment of severe epilepsies.”

The NIH Blueprint collaboration will support Knopp’s advance into human studies in KCNQ2 neonatal epileptic encephalopathy. "The KCNQ2 community appreciates the recognition of the NIH to support the need for innovation in uncommon conditions like KCNQ2 epilepsy,” said Jim Johnson, president of the KCNQ2 Cure Alliance. He noted that the annual KCNQ2 Cure Family and Professional Summit, underway this week in Boston, “is focused on partnership and innovation in the search for effective treatments.”

ABOUT KNOPP BIOSCIENCES LLC

Knopp Biosciences, based in Pittsburgh, PA, USA, is a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need. Our clinical-stage small molecule, dexpramipexole, will be entering late-stage clinical studies in hypereosinophilic syndromes and Phase 2 clinical studies in eosinophilic asthma. Our preclinical platform is directed to small molecule treatments for neonatal epileptic encephalopathy, a devastating brain disorder of infants caused by a rare mutation in the KCNQ2 gene. Please visit knoppbio.com.

ABOUT KCNQ2 CURE ALLIANCE

KCNQ2 Cure Alliance is a non-profit organization dedicated to raising research funds for KCNQ2 epileptic encephalopathy, a rare and catastrophic form of epilepsy beginning in the first days of life. Please visit kcnq2cure.org.

Knopp’s Kv7 research is supported under Award Number U44NS093160 of the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH). The content of this announcement is solely the responsibility of Knopp and does not necessarily represent the views of the NIH.

This press release contains "forward-looking statements," including statements relating to planned regulatory filings and clinical development programs for dexpramipexole. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that dexpramipexole will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market the product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing clinical study to verify their safety and effectiveness.

Contact information

Knopp Biosciences LLC
Tom Petzinger, +1-412-488-1776
tom@knoppbio.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Amedia Selects Aria Systems’ Billing Solution to Manage Digital and Print Subscriptions20.6.2018 11:53Pressemelding

Aria Systems, the leader in helping large enterprises grow subscription- and usage-based revenue, announced today that Amedia, Norway’s largest publisher of local newspapers and second largest media company overall, has selected the company’s billing and monetization solution for its print and digital publications. The selection comes following a yearlong, multi-phased pilot during which Amedia trialed Aria’s platform across multiple dimensions with great success, leading to a multi-year commitment. “Over the past year, Aria was able to successfully demonstrate how transformative its billing and subscription management solution is for a publishing company like Amedia,” said Haakon Johansen, Vice President Consumer Market at Amedia. “We have greater flexibility to manage the large volume of subscriptions across both print and digital titles and better meet the needs of our customers.” As the largest local publisher in Norway, Amedia currently distributes 63 local newspapers that reach a

Enamine and TBD Biodiscovery Collaborate to Provide GMP-Based Services20.6.2018 11:17Pressemelding

Enamine Ltd., a chemical research organization and producer of novel building blocks and screening libraries, and TBD Biodiscovery, a premium GMP manufacturer of fine chemicals including chemical active pharmaceutical ingredients (APIs), today announced they have entered into a collaboration agreement. The partnership aims to manage the transition of chemical synthesis of novel intermediates from laboratory to bulk scale under GMP standards utilizing Enamine’s know-how and process development expertise. This will help researchers meet the manufacturing feasibility criteria required for drug candidate selection, providing a rapid and cost effective scaled supply of new compounds. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180619005582/en/ Enamine’s catalogue of building blocks is the largest in the world and has been widely used by pharmaceutical companies for more than 15 years to develop lead compounds and drug candidat

ABB and Kawasaki Create World’s First Common Interface for Collaborative Robots20.6.2018 11:00Pressemelding

ABB and Kawasaki Heavy Industries, both global leading players in industrial automation and robotics, are showcasing the world’s first common collaborative robot operating interface at automatica in Munich, Germany from June 19-22, 2018. The common interface will also help address the shortage of skilled workers in many industries. In Japan for example, one person in five is within a decade of retirement. Demand for collaborative robots has outpaced the rapidly-growing industrial robot market, as easier-to-use robots open doors to new users. The fact that collaborative robots can be programmed and operated by people without specialized training helps small and medium enterprises, in particular, to leapfrog traditionally longer industrial robot learning curves. Collaborative robots (cobots) that can be operated by nearly any user can help offset labor shortages. Their flexibility to work nearly anywhere in a factory without safety barriers also makes them ideal for meeting sudden and un

CORRECTING and REPLACING Deutsche Bank Moves Reconciliation Services to SmartStream to Further Improve Processing and Reduce Costs20.6.2018 10:38Pressemelding

First paragraph, first sentence of release should read: As part of its transformation strategy, Deutsche Bank has selected SmartStream ... (instead of 'As part of a wider strategy to adopt industry utilities, Deutsche Bank has selected SmartStream ...'). The corrected release reads: DEUTSCHE BANK MOVES RECONCILIATION SERVICES TO SMARTSTREAM TO FURTHER IMPROVE PROCESSING AND REDUCE COSTS As part of its transformation strategy, Deutsche Bank has selected SmartStream Technologies’ Centre of Excellence (CoE) to provide an off-site operations platform - including three services which will allow the bank to streamline, simplify and reduce the costs of its reconciliations environment. With the growth in volume of reconciliations, the processing of large quantities of data has become complex. Many financial institutions are exploring utilities to ensure accuracy and cost savings. With the addition of the CoE to Deutsche Bank, SmartStream will provide the bank with three distinct managed servic

Hotelsclick.com: You Can Pay the Hotel with Amazon Pay20.6.2018 10:32Pressemelding

Hotelsclick.com, the Italy-based online booking for hotels, has integrated Amazon Pay into its payment methods, becoming one of the first OTA in Europe offering this service. Besides traditional payment methods, such as credit cards (included Amex) and Paypal, users that book a hotel on Hotelsclick.com and hold an Amazon account can choose Amazon Pay to complete the reservation: they only need to enter their Amazon username and password during the checkout process on Hotelsclick.com and the transaction will be carried out quick and safe. As a matter of fact, making an online reservation will be more and more easy thanks to Amazon Pay. Users will no longer need to enter multiple password or other payment details: all information will be automatically taken from their Amazon account. “We are very proud to bring Amazon Pay to our users who visit us on their PCs and mobile. Customers’ experience is our main concern: adding Amazon Pay we are confident we can consistently improve it, making

UEC Presents Its Latest Solution for Gas Transportation and Power Generation at MIOGE 201820.6.2018 09:55Pressemelding

United Engine Corporation of Rostec Corporation takes part in the 15th Moscow International Oil and Gas Exhibition (MIOGE 2018). There it will demonstrate gas turbine gas compressor and power generating sets, which are the most promising on the Russian and foreign markets. UEC's exhibition booth presents layouts of gas pumping unit GPA-16, Katangli power facility, and Novoprivodinskaya compressor station. The companies of Russian fuel and energy complex —Gazprom, NC Rosneft, Lukoil, Surgutneftegas and others — are the main consumers of power and gas pumping units produced by UEC. To date, Gazpom uses around 1,500 industrial engines manufactured by the corporation. UEC is going to increase the share of gas turbine industrial equipment in the total volume of its supplies. The corporation is actively performing its activities aimed at entering foreign markets. In May 2018, UEC introduced its latest developments at the exhibitions Iran Oil Show in Tehran, Oil & Gas Uzbekistan in Tashkent a